Efficacy of paroxetine for the treatment of depression in the context of HIV infection

Barbara Grassi, Orsola Gambini, G. Garghentini, A. Lazzarin, S. Scarone

Research output: Contribution to journalArticlepeer-review

Abstract

Recent studies in the literature point out that HIV-infected subjects are affected by depression with a relatively high frequency. The aim of this study was to assess the efficacy and tolerability of paroxetine for the treatment of depression in the context of HIV infection. 15 HIV-infected subjects (10 patients with a major depressive episode and 5 patients with an adjustment disorder with depressed mood, according to the DSM IV diagnostic criteria) were administered paroxetine at a daily dosage of 20 mg. Depressive symptomatology was monitored by means of the Hamilton Rating Scale for Depression (HAM-D) at the time of enrollment and 2 weeks, 4 weeks, and 6 weeks later; at the same times adverse effects were recorded. 14 patients completed the study, and all of these recovered from depression; HAM-D mean scores significantly improved from baseline to final assessment, both when all subjects were considered (ANOVA for repeated measurements: p ≤ 0.0001) and when only patients with a major depressive episode were included in the statistical analysis (ANOVA for repeated measurements: p <0.0001). No significant adverse effects were recorded. Because of its efficacy and good tolerability paroxetine seems to be suitable for the treatment of depression in the context of HIV infection.

Original languageEnglish
Pages (from-to)70-71
Number of pages2
JournalPharmacopsychiatry
Volume30
Issue number2
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Efficacy of paroxetine for the treatment of depression in the context of HIV infection'. Together they form a unique fingerprint.

Cite this